Search results for "cAMP"

showing 10 items of 1995 documents

Irinotecan (CPT-11) and Mitomycin-C (MMC) as Second-Line Therapy in Advanced Gastric Cancer

2005

Objective The aim of this study was to evaluate the activity and toxicity of a combination regimen of CPT-11 and mitomycin-c as second-line chemotherapy for pretreated patients with advanced, metastatic, or both, gastric adenocarcinoma. Materials and methods Patients with pretreated metastatic disease or early relapsed after adjuvant chemotherapy were enrolled. Entry criteria included histologic/cytologic diagnosis of gastric adenocarcinoma, age 18 to 75 years, performance status > or =70 (Karnofsky scale), bi-dimensionally measurable disease. Patients received CPT-11 and mitomycin-c at the dosage of 150 mg/m2 on days 1 and 15, and 8 mg/m2 on day 1, respectively, every 4 weeks. The disease …

AdultMaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaMitomycinmedicine.medical_treatmentSalvage therapyPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanGastroenterologyDisease-Free SurvivalStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansLife TablesPeritoneal NeoplasmsAgedSalvage TherapyChemotherapyLeukopeniaPerformance statusbusiness.industryLiver NeoplasmsDrug SynergismMiddle Agedmedicine.diseaseSurvival Analysistherapy gastric cancerIrinotecanRegimenTreatment OutcomeItalyOncologyLymphatic MetastasisCamptothecinFemalemedicine.symptombusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer

2014

<b><i>Purpose:</i></b> Fluoropyrimidines, oxaliplatin, irinotecan and targeted therapies represent the standard treatment of metastatic colorectal cancer. After failure of all these treatments, few options are available. In such chemorefractory patients the effect of triplet chemotherapy with bevacizumab (FOLFIRINOX bevacizumab) has never been investigated. <b><i>Patients and Methods:</i></b> 49 consecutive patients bearing unresectable metastatic colorectal cancer and who experienced failure to oxaliplatin- and irinotecan-based chemotherapy were treated with oxaliplatin (85 mg/m<sup>2</sup>), irinotecan (180 mg/m<sup>2</s…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsBevacizumabFOLFIRINOXColorectal cancerLeucovorinSalvage therapyAntibodies Monoclonal HumanizedIrinotecanInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesSurvival rateAgedNeoplasm StagingAged 80 and overSalvage Therapybusiness.industryLiver NeoplasmsGeneral MedicineMiddle AgedPrognosismedicine.diseasedigestive system diseasesOxaliplatinBevacizumabOxaliplatinSurvival RateIrinotecanOncologyDrug Resistance NeoplasmFluorouracilCamptothecinFemaleFluorouracilColorectal NeoplasmsbusinessFollow-Up Studiesmedicine.drugOncology
researchProduct

Final results from a randomized phase 3 study of FOLFIRI \pm$ panitumumab for second-line treatment of metastatic colorectal cancer

2013

Abstract: Background: The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab-FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported. Patients and methods: Patients receiving one prior mCRC treatment were randomly assigned (1:1) to panitumumab (6.0 mg/kg)-FOLFIRI versus FOLFIRI every 2 weeks. Co-primary end points (PFS and OS) were prospectively analyzed by tumor KRAS status. Results: One thousand one hundred and eighty-six patient…

AdultMaleOncologymedicine.medical_specialtyBevacizumabColorectal cancerLeucovorinPhases of clinical researchKaplan-Meier Estimatemedicine.disease_causeSkin DiseasesDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPanitumumabProgression-free survivalAgedAged 80 and overbusiness.industryPanitumumabLiver NeoplasmsHazard ratioAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseTreatment OutcomeOncologyQuality of LifeFOLFIRICamptothecinFemaleFluorouracilKRASHuman medicineColorectal Neoplasmsbusinessmedicine.drugAnnals of oncology
researchProduct

Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicente…

2006

This study was designed to evaluate the efficacy and safety of irinotecan/cetuximab administered as third- or fourth-line therapy in a retrospective series of patients with metastatic colorectal cancer refractory to oxaliplatin and irinotecan. Patients and Methods: Most patients (90%) had been previously treated with adjuvant 5-fluorouracil/leucovorin, and all had received oxaliplatin-based regimens before receiving irinotecan- based second-line treatment. Sixty patients with irinotecan-refractory colorectal cancer received a regimen comprising weekly irinotecan 120 mg/m 2 as a 1-hour intravenous infusion and cetuximab 400 mg/m 2 infused over 2 hours as the initial dose and 250 mg/m 2 infus…

AdultMaleOncologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSettore MED/06 - Oncologia MedicaColorectal cancermedicine.medical_treatmentCetuximabAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisSurvival analysisAgedAged 80 and overChemotherapyCetuximabPerformance statusbusiness.industryGastroenterologyAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesOxaliplatinErbB ReceptorsIrinotecanSettore MED/18 - Chirurgia GeneraleRegimenOncologyCamptothecinFemaleEpidermal growth factor receptor Oxaliplatin Vascular endothelial growth factorColorectal Neoplasmsbusinessmedicine.drugClinical Colorectal Cancer
researchProduct

Cerebral activation in patients with somatoform pain disorder exposed to pain and stress: an fMRI study.

2006

Patients with somatoform pain disorders are supposed to suffer from an early acquired defect in stress regulation. In order to look for common alterations of the pain- and stress-responsive cortical areas, we prospectively recorded cerebral activations induced by pin-prick pain, by cognitive stress and emotional stress using functional magnetic resonance imaging (fMRI) in a group of 17 patients and an age-matched control group. In addition, the hippocampal volumes of both groups were measured. Patients showed increased activations of the known pain-processing areas (thalamus, basal ganglia, operculo-insular cortex), but also of some prefrontal, temporal and parietal regions during first pai…

AdultMalePain ThresholdCognitive NeuroscienceThalamusAction PotentialsPainHippocampal formationSomatosensory systemSuperior temporal gyrusStress PhysiologicalEvoked Potentials SomatosensoryBasal gangliaThreshold of painmedicineHumansSomatoform DisordersBrain Mappingmedicine.diagnostic_testBrainMiddle AgedAnticipationMagnetic Resonance ImagingNeurologyFemaleFunctional magnetic resonance imagingPsychologyNeuroscienceNeuroImage
researchProduct

Perceptual correlates of nociceptive long-term potentiation and long-term depression in humans.

2004

Long-term potentiation (LTP) and long-term depression (LTD) of synaptic strength are ubiquitous mechanisms of synaptic plasticity, but their functional relevance in humans remains obscure. Here we report that a long-term increase in perceived pain to electrical test stimuli was induced by high-frequency electrical stimulation (HFS) (5 × 1 sec at 100 Hz) of peptidergic cutaneous afferents (27% above baseline, undiminished for >3 hr). In contrast, a long-term decrease in perceived pain (27% below baseline, undiminished for 1 hr) was induced by low-frequency stimulation (LFS) (17 min at 1 Hz). Pain testing with punctate mechanical probes (200 μm diameter) in skin adjacent to the HFS–LFS con…

AdultMalePain ThresholdLong-Term PotentiationPainStimulationNeocortexBehavioral/Systems/CognitiveHippocampusSensitivity and SpecificitySynaptic TransmissionConditioning PsychologicalmedicineHumansLong-term depressionPain MeasurementSkinAnalysis of VarianceHypoalgesiaNeuronal Plasticityintegumentary systemGeneral NeuroscienceLong-Term Synaptic DepressionNociceptorsLong-term potentiationMiddle AgedElectric StimulationForearmAllodyniaNociceptionSpinal CordSynaptic plasticityHyperalgesiaFemalemedicine.symptomPsychologyNeuroscienceThe Journal of neuroscience : the official journal of the Society for Neuroscience
researchProduct

Subregional Pathology of the Amygdala Complex and Entorhinal Region in Surgical Specimens From Patients With Pharmacoresistant Temporal Lobe Epilepsy

2000

The hippocampus, amygdala complex, and entorhinal region represent anatomically linked limbic structures of the mesiotemporal lobe. Chronic seizures and mnestic deficits in patients with pharmacoresistant mesial temporal lobe epilepsy (TLE) appear to correlate with distinct patterns of histopathological alterations in these areas. The complex anatomical organization of the amygdala and entorhinal region, however, render a detailed neuropathological evaluation of surgical specimens difficult. In this study, we present a combined cytoarchitectonical, pigmentarchitectonical, myelinarchitectonical, and immunohistochemical reconstruction of the amygdala, entorhinal region, and hippocampus from s…

AdultMalePathologymedicine.medical_specialtyAdolescentDrug ResistanceHippocampusAutopsyAmygdalaPathology and Forensic MedicineTemporal lobeCentral nervous system diseaseCellular and Molecular NeuroscienceEpilepsyBasal (phylogenetics)medicineEntorhinal CortexHumansGliosisSclerosisGeneral MedicineMiddle AgedAmygdalamedicine.diseaseTemporal LobeLobemedicine.anatomical_structureEpilepsy Temporal Lobenervous systemNeurologyChild PreschoolAnticonvulsantsFemaleNeurology (clinical)Psychologypsychological phenomena and processesJournal of Neuropathology & Experimental Neurology
researchProduct

Hsp60 response in experimental and human temporal lobe epilepsy

2015

The mitochondrial chaperonin Hsp60 is a ubiquitous molecule with multiple roles, constitutively expressed and inducible by oxidative stress. In the brain, Hsp60 is widely distributed and has been implicated in neurological disorders, including epilepsy. A role for mitochondria and oxidative stress has been proposed in epileptogenesis of temporal lobe epilepsy (TLE). Here, we investigated the involvement of Hsp60 in TLE using animal and human samples. Hsp60 immunoreactivity in the hippocampus, measured by Western blotting and immunohistochemistry, was increased in a rat model of TLE. Hsp60 was also increased in the hippocampal dentate gyrus neurons somata and neuropil and hippocampus proper …

AdultMalePathologymedicine.medical_specialtyanimal structuresHippocampuschemical and pharmacologic phenomenaBiologyHippocampal formationHippocampuscomplex mixturesEpileptogenesisArticleTemporal lobeYoung AdultEpilepsymedicineNeuropilAnimalsHumansTemporal lobe epilepsyMultidisciplinaryHippocampus properDentate gyrusfungiChaperonin 60Middle Agedmedicine.diseaseImmunohistochemistryRatsmedicine.anatomical_structureEpilepsy Temporal Lobenervous systemDentate GyrusFemale
researchProduct

Perceptual Correlate of Nociceptive Long-Term Potentiation (LTP) in Humans Shares the Time Course of Early-LTP

2006

As in neocortex and hippocampus, neurons in the dorsal horn of the spinal cord develop long-term potentiation of synaptic efficacy (LTP) on high-frequency stimulation (HFS) of their afferent input, although how long LTP lasts in this nociceptive relay nucleus has not yet been addressed. Here we studied neurogenic hyperalgesia, a perceptual correlate of nociceptive LTP, in 13 healthy subjects, after HFS (5 × 1 s at 100 Hz) of superficial cutaneous afferents. HFS led to a mean upward shift of the stimulus–response function for pinprick-evoked pain (punctate mechanical hyperalgesia) in all subjects by a factor of 2.5 ( P < 0.001) that lasted undiminished for the initial 1-h observation per…

AdultMalePhysiologyLong-Term PotentiationPainHippocampusStimulationPhysical StimulationConditioning PsychologicalmedicineHumansNeurons AfferentPain MeasurementNeocortexGeneral NeuroscienceNociceptorsLong-term potentiationSpinal cordElectric StimulationNociceptionmedicine.anatomical_structureHyperalgesiaData Interpretation StatisticalTime courseHyperalgesiaVisual PerceptionFemalemedicine.symptomPsychologyNeuroscienceJournal of Neurophysiology
researchProduct

Increased amygdala and parahippocampal gyrus activation in schizophrenic patients with auditory hallucinations: An fMRI study using independent compo…

2010

Objective: Hallucinations in patients with schizophrenia have strong emotional connotations. Functional neuroimaging techniques have been widely used to study brain activity in patients with schizophrenia with hallucinations or emotional impairments. However, few of these Studies have investigated the association between hallucinations and emotional dysfunctions using an emotional auditory paradigm. Independent component analysis (ICA) is an analysis method that is especially useful for decomposing activation during complex cognitive tasks in which multiple operations occur simultaneously. Our aim in this Study is to analyze brain activation after the presentation of emotional auditory stim…

AdultMalePsychosisFACIAL EXPRESSIONSHallucinationsBrain activity and meditationDIFFERENTIAL NEURAL RESPONSENEUROBIOLOGYFEARFUL FACESIndependent component analysisAuditory hallucinationsAmygdalaSeverity of Illness IndexPSYCHOSISFunctional neuroimagingBrief Psychiatric Rating ScalemedicineEMOTIONHumansBRAINBiological PsychiatryAuditory hallucinationSALIENCEmedicine.diagnostic_testABNORMALITIESfMRIRECOGNITIONmedicine.diseaseAmygdalaMagnetic Resonance ImagingAuditory emotional paradigmPsychiatry and Mental healthmedicine.anatomical_structureSchizophreniaParahippocampal Gyrusmedicine.symptomPsychologyFunctional magnetic resonance imagingBrain activityNeuroscienceParahippocampal gyrus
researchProduct